Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pascal pushes AZ to push Brilinta in diabetes

This article was originally published in Scrip

Executive Summary

AstraZeneca's re-announcement on 5 December that it will open two new large trials of its commercially less-than-brilliant antiplatelet drug Brilinta (ticagrelor) is further evidence that the company is responding to stinging public criticism from its still untarnished CEO Pascal Soriot. In the company's latest attempt to put the drug back on commercial track, Brilinta (Brilique or Possia outside the US) will be tested in two sets of high cardiovascular risk patients representing hundreds of millions of patients worldwide – type 2 diabetics, on the one hand, and those who have suffered non-fatal ischemic disease on the other. In the diabetes trial, the fact that ticagrelor will go head-to-head with aspirin suggests that AstraZeneca may be willing to be aggressive in combatting the aspirin contraindication that Brilinta/Brilique currently carries.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts